High risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro.
<h4>Background</h4>Oral contraceptive (OC) use increases venous thromboembolism risk 2-5-fold. Procoagulant changes can be detected in plasma from OC users even without thrombosis, but cellular mechanisms that provoke thrombosis have not been identified. Endothelial cell (EC) dysfunction...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0284333&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850034371843588096 |
|---|---|
| author | Emma G Bouck Marios Arvanitis William O Osburn Yaqiu Sang Paula Reventun Homa K Ahmadzia Nicholas L Smith Charles J Lowenstein Alisa S Wolberg |
| author_facet | Emma G Bouck Marios Arvanitis William O Osburn Yaqiu Sang Paula Reventun Homa K Ahmadzia Nicholas L Smith Charles J Lowenstein Alisa S Wolberg |
| author_sort | Emma G Bouck |
| collection | DOAJ |
| description | <h4>Background</h4>Oral contraceptive (OC) use increases venous thromboembolism risk 2-5-fold. Procoagulant changes can be detected in plasma from OC users even without thrombosis, but cellular mechanisms that provoke thrombosis have not been identified. Endothelial cell (EC) dysfunction is thought to initiate venous thromboembolism. It is unknown whether OC hormones provoke aberrant procoagulant activity in ECs.<h4>Objective</h4>Characterize the effect of high-risk OC hormones (ethinyl estradiol [EE] and drospirenone) on EC procoagulant activity and the potential interplay with nuclear estrogen receptors ERα and ERβ and inflammatory processes.<h4>Methods</h4>Human umbilical vein and dermal microvascular ECs (HUVEC and HDMVEC, respectively) were treated with EE and/or drospirenone. Genes encoding the estrogen receptors ERα and ERβ (ESR1 and ESR2, respectively) were overexpressed in HUVEC and HDMVEC via lentiviral vectors. EC gene expression was assessed by RT-qPCR. The ability of ECs to support thrombin generation and fibrin formation was measured by calibrated automated thrombography and spectrophotometry, respectively.<h4>Results</h4>Neither EE nor drospirenone, alone or together, changed expression of genes encoding anti- or procoagulant proteins (TFPI, THBD, F3), integrins (ITGAV, ITGB3), or fibrinolytic mediators (SERPINE1, PLAT). EE and/or drospirenone did not increase EC-supported thrombin generation or fibrin formation, either. Our analyses indicated a subset of individuals express ESR1 and ESR2 transcripts in human aortic ECs. However, overexpression of ESR1 and/or ESR2 in HUVEC and HDMVEC did not facilitate the ability of OC-treated ECs to support procoagulant activity, even in the presence of a pro-inflammatory stimulus.<h4>Conclusions</h4>The OC hormones EE and drospirenone do not directly enhance thrombin generation potential of primary ECs in vitro. |
| format | Article |
| id | doaj-art-8a4b7500898a4dea84b13d6da7d48daf |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-8a4b7500898a4dea84b13d6da7d48daf2025-08-20T02:57:52ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01184e028433310.1371/journal.pone.0284333High risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro.Emma G BouckMarios ArvanitisWilliam O OsburnYaqiu SangPaula ReventunHoma K AhmadziaNicholas L SmithCharles J LowensteinAlisa S Wolberg<h4>Background</h4>Oral contraceptive (OC) use increases venous thromboembolism risk 2-5-fold. Procoagulant changes can be detected in plasma from OC users even without thrombosis, but cellular mechanisms that provoke thrombosis have not been identified. Endothelial cell (EC) dysfunction is thought to initiate venous thromboembolism. It is unknown whether OC hormones provoke aberrant procoagulant activity in ECs.<h4>Objective</h4>Characterize the effect of high-risk OC hormones (ethinyl estradiol [EE] and drospirenone) on EC procoagulant activity and the potential interplay with nuclear estrogen receptors ERα and ERβ and inflammatory processes.<h4>Methods</h4>Human umbilical vein and dermal microvascular ECs (HUVEC and HDMVEC, respectively) were treated with EE and/or drospirenone. Genes encoding the estrogen receptors ERα and ERβ (ESR1 and ESR2, respectively) were overexpressed in HUVEC and HDMVEC via lentiviral vectors. EC gene expression was assessed by RT-qPCR. The ability of ECs to support thrombin generation and fibrin formation was measured by calibrated automated thrombography and spectrophotometry, respectively.<h4>Results</h4>Neither EE nor drospirenone, alone or together, changed expression of genes encoding anti- or procoagulant proteins (TFPI, THBD, F3), integrins (ITGAV, ITGB3), or fibrinolytic mediators (SERPINE1, PLAT). EE and/or drospirenone did not increase EC-supported thrombin generation or fibrin formation, either. Our analyses indicated a subset of individuals express ESR1 and ESR2 transcripts in human aortic ECs. However, overexpression of ESR1 and/or ESR2 in HUVEC and HDMVEC did not facilitate the ability of OC-treated ECs to support procoagulant activity, even in the presence of a pro-inflammatory stimulus.<h4>Conclusions</h4>The OC hormones EE and drospirenone do not directly enhance thrombin generation potential of primary ECs in vitro.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0284333&type=printable |
| spellingShingle | Emma G Bouck Marios Arvanitis William O Osburn Yaqiu Sang Paula Reventun Homa K Ahmadzia Nicholas L Smith Charles J Lowenstein Alisa S Wolberg High risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro. PLoS ONE |
| title | High risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro. |
| title_full | High risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro. |
| title_fullStr | High risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro. |
| title_full_unstemmed | High risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro. |
| title_short | High risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro. |
| title_sort | high risk oral contraceptive hormones do not directly enhance endothelial cell procoagulant activity in vitro |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0284333&type=printable |
| work_keys_str_mv | AT emmagbouck highriskoralcontraceptivehormonesdonotdirectlyenhanceendothelialcellprocoagulantactivityinvitro AT mariosarvanitis highriskoralcontraceptivehormonesdonotdirectlyenhanceendothelialcellprocoagulantactivityinvitro AT williamoosburn highriskoralcontraceptivehormonesdonotdirectlyenhanceendothelialcellprocoagulantactivityinvitro AT yaqiusang highriskoralcontraceptivehormonesdonotdirectlyenhanceendothelialcellprocoagulantactivityinvitro AT paulareventun highriskoralcontraceptivehormonesdonotdirectlyenhanceendothelialcellprocoagulantactivityinvitro AT homakahmadzia highriskoralcontraceptivehormonesdonotdirectlyenhanceendothelialcellprocoagulantactivityinvitro AT nicholaslsmith highriskoralcontraceptivehormonesdonotdirectlyenhanceendothelialcellprocoagulantactivityinvitro AT charlesjlowenstein highriskoralcontraceptivehormonesdonotdirectlyenhanceendothelialcellprocoagulantactivityinvitro AT alisaswolberg highriskoralcontraceptivehormonesdonotdirectlyenhanceendothelialcellprocoagulantactivityinvitro |